Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...
With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...
Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Clinical Trials Arena on MSN
Gilead’s HIV ART combo deemed non-inferior in second phase III trial
"Gilead’s HIV ART combo deemed non-inferior in second Phase III trial" was originally created and published by Clinical ...
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the ...
Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...
By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results